Elite in Acute Lymphoblastic Leukemia (ALL)

Thibaut T. Leguay

Bordeaux, FR 
Elite in Acute Lymphoblastic Leukemia (ALL)
Bordeaux, FR 
OverviewLocationsClinical Research

Overview

Thibaut Leguay practices in Bordeaux, France. Leguay is rated as an Elite expert by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Their top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Adult T-Cell Leukemia, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 76 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 43 articles and participated in 1 clinical trial in the study of Acute Lymphoblastic Leukemia (ALL).

Locations

Bordeaux, France
Other Locations
Pessac-sur-dordogne, France
Caen, France
Toulouse, France
CHU Hotel Dieu
Nantes, France
Université Paris Est, CHU, Grenoble, France
CHU
Angers, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3
Phase II, Multicenter, Open Label, Prospective to Evaluate Efficacy and Tolerance of a Chemoimmunotherapy With HyperCVAD or Vincristine/Dexamethasone Plus the Anti-CD22 Monovlonal Antobody Epratuzumab for the Treatment of Adult Relapsed/Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients : CHEPRALL Study, a GRAALL Study.
Phase II, Multicenter, Open Label, Prospective to Evaluate Efficacy and Tolerance of a Chemoimmunotherapy With HyperCVAD or Vincristine/Dexamethasone Plus the Anti-CD22 Monovlonal Antobody Epratuzumab for the Treatment of Adult Relapsed/Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients : CHEPRALL Study, a GRAALL Study.
Enrollment Status: Completed
Publish Date: February 27, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

76 Total Publications

Intermediate-Dose Cytarabine as Postinduction AML Therapy.
Intermediate-Dose Cytarabine as Postinduction AML Therapy.
Journal: NEJM evidence
Published: June 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Leguay's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile